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Cutaneous T-cell lymphomas (CTCL), especially myco-
sis fungoides, can be considered as a state of longstan-
ding low-grade systemic inflammation. Many studies 
have focused on secondary cancers with CTCL, but in-
formation about comorbidities is limited. A total of 144 
patients with CTCL at Helsinki University Central Hos-
pital during 2005 to 2015 were studied to determine 
associated comorbidities and causes of death in this 
cohort. Compared with an age-standardized control 
population, the prevalence of type 2 diabetes mellitus 
was increased among patients with CTCL with no link 
to obesity. Patients with CTCL had a lower prevalence 
of hypertension, myocardial infarction and stroke than 
the control group. The 3 most common causes of death 
were CTCL, coronary artery disease and lung cancer. 
The increased risk of myocardial infarction or stroke 
reported previously was not detected in this patient 
group.
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Cutaneous T-cell lymphomas (CTCL) are a rare group of non-Hodgkin’s lymphomas in which neoplastic 
cells primarily home to the skin. The most common type 
of CTCL is mycosis fungoides (MF), the clinical course 
of which is usually very indolent, depending on the stage 
of the disease. In the early stages the prognosis is favou-
able, but progression to tumours or nodal involvement 
predicts a poor prognosis (1). Sézary syndrome (SS) and 
subcutaneous panniculitis-like T-cell lymphoma (SPTL) 
are rare forms of CTCL. SS is understood to arise from 
a different subset of T cells (central memory cells) and 
is currently not considered to be a leukaemic variant of 
MF, where the cells arise from skin resident-effector 
memory T cells (2).
MF is understood to arise through longstanding 
chronic inflammation, and can be considered as a state 
of longstanding low-grade systemic inflammation (3). 
Chronic systemic inflammation has recently been accep-
ted to be an important contributor to metabolic diseases. 
Inflammatory mediators released in chronic inflamma-
tion can lead to hypertension, type 2 diabetes mellitus 
(DM2) and atherogenesis (4, 5). Psoriasis is an example 
of chronic systemic inflammation with an elevated risk of 
cardiovascular diseases. In addition, patients with atopic 
dermatitis appear to have increased risk of cardiovascular 
disease, heart attack and stroke (6, 7). In advanced stages 
of CTCL the immunoprofile is polarized towards Th2-
activated memory cells, similarly to atopic dermatitis.
Most previous studies of comorbidities in CTCL have 
focussed on cancer. These studies have demonstrated 
an increased risk of secondary cancers in patients with 
CTCL (8–11). There are only a few previous studies 
concerning other comorbidities in CTCL (12–14). In 
MF the recently reported increased risk of myocardial 
infarction may be mediated by chronic inflammation 
(14). Evaluation of cardiovascular risk factors in 
patients with MF has demonstrated an increased rate 
of cardiovascular risk related to higher levels of total 
cholesterol and low-density lipoprotein (LDL) choles-
terol than in control patients (12). Interestingly, MF 
has also been linked to increased risk of anxiety and 
depression (13).
The prognosis and survival of patients with CTCL is 
dependent on the stage of the disease (15–17). Patients 
with non-advanced stages of CTCL seldom die of the 
disease itself, and reports of causes of death in this patient 
group are sparse. 
The aims of this study were to examine comorbidi-
ties in the largest cohort of Finnish patients with CTCL 
and to assess the most common causes of death in this 
patient group.
PATIENTS AND METHODS
A total of 144 patients with CTCL, treated in the Skin and Allergy 
Hospital, Helsinki University Central Hospital (HUCH), Helsinki, 
Finland, during the period 1 January 2005 to 18 February 2015 
were analysed retrospectively. 
Patient search was based on a confirmed dermatological and 
histopathological diagnosis. The majority of patients had a di-
agnosis of MF (n = 122). There were 8 patients with SS, 8 with 
SPTL, and 6 with anaplastic large cell lymphoma. All except one 
of the patients with SPTL had an αβ-phenotype. Clinical patient 
data and comorbidity data was collected from the comprehen-
sive electronic medical patient records of HUCH. Staging of 
the patients was performed according to current guidelines (15). 
Systemic treatment information was also collected from patient 
charts. Demographic and survival data for the 144 CTCL patients 
is presented in Table I. 
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The prevalence of coronary artery disease, hypertension, stroke, 
myocardial infarction and DM2 was compared with that of a stan-
dardized, representative sample of the Finnish general population. 
The data for the general population came from the National Health 
2000 Examination Survey (n = 8,028) representing the Finnish po-
pulation aged 30 years and over (18). For this analysis individuals 
within the age range of the patients were selected (n = 6,268). This 
sample of the general population was weighted to reflect the age 
distribution of the patients. The prevalence of the diseases in the 
population data is based on confirmed diagnoses, which, in turn, 
are based either on a medical examination as a part of the survey 
or on medical records and register data.
The statistical significance of the difference in the prevalence of 
the diseases between the groups was tested using χ2 tests (2-sided 
likelihood ratio test and Fisher’s exact test). p-values < 0.05 were 
considered statistically significant.
Detailed causes of death were obtained from Statistics Finland.
RESULTS
The study cohort consisted of 144 patients who were 
followed up for 10 years. The majority (65%) of the pa-
tients were men and 35% were female and the majority 
(n = 122) had MF (Table I). The mean age at diagnosis 
was 66.4 years. Different CTCL subtypes according to 
age group are presented in Table II. There were 6 patients 
who had more than 3 malignancies in addition to CTCL. 
The most common other types of cancer were lung can-
cer, prostate cancer, colorectal cancer and bladder cancer.
The majority of the patients in this study were stage 
IA–IIA (70%). Hypercholesterolaemia was detected 
in 46/144 patients (32%). Only 23 patients (16%) had 
received retinoid therapy and 9 of them (40%) had 
hypercholesterolemia. None of these 9 patients died of 
coronary artery disease or myocardial infarction. Eight 
patients had received doxorubicin, but none of them had 
myocardial infarction.
Overall prevalence data for coronary artery disease, 
hypertension, myocardial infarction, stroke, and diabetes 
mellitus in the patient and controls cohort are shown in 
Table III. Five of the 144 patients had experienced stroke 
and one patient had experienced transient ischaemic 
attack. Only one patient had experienced myocardial 
infarction. The prevalence of coronary artery disease, 
hypertension, myocardial infarction and stroke was 
statistically lower than in the control group.
All cases of diabetes mellitus in the CTCL cohort were 
of type 2, and the prevalence was statistically higher 
than in the age-matched control group (Table III). In 
the patient records, 23 patients (16%) had a mention of 
obesity and 54 (37.5%) were smokers.
During the follow-up time, 31/144 patients died. The 
3 most common causes of death were cutaneous lym- 
p homa (n = 12), coronary artery disease (n = 5) and lung 
cancer (n = 4). The 12 deceased cutaneous lymphoma 
patients consisted of 8 MF, 2 SS and 2 primary anaplastic 
large cell lymphoma subtypes. Four patients died of lung 
cancer (Table IV).
DISCUSSION
There are only a few studies of comorbidities in patients 
with CTCL. The risk of myocardial infarction and stroke 
was found to be increased in patients with CTCL in a 







Mean age at diagnosis (years) 66.4
Alive (%) 78
Cutaneous T-cell lymphomas diagnosis
  Mycosis fungoides, n 122
  Sézary syndrome, n 8
  Panniculitis-like T-cell lymphoma, n 8
  Primary cutaneous anaplastic large cell lymphoma, n 6
Table III. Prevalence of different diseases in patients with cutaneous 














Coronary artery disease 17 (11.8) 1,238 (19.8) 0.012 0.019
Hypertension 71 (49.3) 3,804 (60.7) 0.006 0.007
Myocardial infarction 1 (0.7) 429 (6.9) < 0.001 < 0.001
Stroke 5 (3.5) 547 (8.7) 0.013 0.023
Type 2 diabetes mellitus 24 (16.7) 615 (9.8) 0.012 0.011
aLikelihood ratio test; bFisher’s exact test.
Table IV. Cause of death in cutaneous T-cell lymphomas (CTCL) 
subtypes
CTCL subtype Cause of death, n
Mycosis fungoides (n = 21) MF 8
Cancer (colon, prostate) 4





Sézary syndrome (n = 8) Sézary syndrome 2
Lung cancer 2
Alcoholic hepatic failure 2
Coronary artery disease 2
PCALCL (n = 6) PCALCL 2a
SPTL (n = 6) Panniculitis-like T-cell lymphoma 0b
aFour patients are alive. bAll patients alive.
PCALCL: primary cutaneous anaplastic large cell lymphoma; SPTL: subcutaneous 
panniculitis-like T-cell lymphoma.





syndrome, n SPTL, n PCALCL, n
20–29 years 1 0 1 0
30–39 years 0 0 3 2
40–49 years 3 1 1 0
50–59 years 14 2 0 0
60–69 years 45 3 2 3
70–79 years 29 2 1 0
> 80 years 30 0 0 1
SPTL: subcutaneous panniculitis-like T-cell lymphoma; PCALCL: primary cutaneous 
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Danish cohort of 483 patients with MF and 623 with 
parapsoriasis (14). In this study, the risk was increased 
within the first 5 years after diagnosis. Our analysis 
of 144 patients with CTCL did not find any increased 
risk of coronary artery disease compared with an age-
standardized control population. Causes of death were 
obtained from Statistics Finland using the main cause 
of death. In our control population it was not possible 
to detect myocardial infarction, but only coronary artery 
disease. Coronary artery disease does not always end in 
myocardial infarction. Our study was retrospective and 
thus dependent on the recorded events. Some diagnoses 
may not have been recorded, although, for example, 
myocardial infarction and stroke usually are the main 
events in deteriorating health and are usually mentioned 
in patient charts. Regarding specific causes of death of 
the patients with CTCL, 1 myocardial infarction and 2 
strokes were found.
A previous study evaluating cardiovascular risk factors 
in patients with MF has reported that patients with MF 
have increased risk of cardiovascular diseases (12). In 
particular, levels of total cholesterol and low-density 
lipoprotein were significantly higher in patients with 
MF. We could only collect a diagnosis of hypercho-
lesterolaemia from the patient charts (32%), but could 
not perform any risk analysis with our control material. 
Patients with CTCL are often treated with retinoids, but 
hyperchlolesterolaemia is controlled with concomitant 
anti-lipid drugs routinely used during treatment. In our 
patients hypercholesterolaemia was not related to death.
The majority of our patients with CTCL were not in 
an advanced stage of the disease. Thus, most of the treat-
ments this cohort had were skin directed. Only 8 patients 
had experienced doxorubicin treatment. Only one patient 
died of myocardial infarction, but he was not treated with 
doxorubicin. Thus, we think that the common known 
cardiotoxic effect of this drug did not have any impact 
on the results. The patients in this study seldom received 
anti-neoplastic drugs or poly-chemotherapies because 
only a small proportion of them were at an advanced 
stage of the disease. 
Our patients had an increased prevalence of DM2 
compared with the control group, and obesity was not 
linked to DM2. There are no previous reports regarding 
DM2 in patients with CTCL. Fallah et al. (19) reported 
autoimmune diseases associated with non-Hodgkin’s 
lymphoma (NHL), but no association with DM type I 
with a higher risk of NHL was found. Obesity has been 
linked to MF in a previous article (20). In obesity, the 
chronic low-grade inflammation of fat tissue releases 
proinflammatory cytokines, which are responsible for 
regulation of T-cell responses favouring lymphoma-
genesis (21). The association of obesity and the risk of 
non-Hodgkin’s lymphomas has been reviewed by Lars-
son & Wolk (22), who found that elevated body mass 
index (BMI) was associated with increased risk of NHL.
Our control group comprised 6,268 participants in the 
National Health 2000 Health Examination survey car-
ried out in the period 2000 to 2001. These individuals 
were in the age range of the patients from the original 
representative sample of 8,028 of the Finnish general 
population aged 30 years and over. The data are based 
on home interviews and medical examination, comple-
mented by medical records and register data. 
In our cohort, the most common cause of death was 
CTCL; it was registered as a primary cause of death in 
32% of this group of patients. In a recent Danish study, 
the comparative percentage was 27% (9). The most com-
mon other cancer-related cause of death was lung cancer, 
which has been reported previously to be increased in 
patients with MF (3, 5). Although the prognosis of SS is 
poor and survival is low, only 2 of our 8 patients with SS 
died of the disease itself. Interestingly, the other causes 
of death in this subgroup were lung cancer, myocardial 
infarction and alcoholic hepatic failure in equal propor-
tions.
In conclusion, this study reports comorbidities in 
Finnish patients with CTCL. An increased prevalence 
of DM2 was found, but the previous observation of 
increased risk of myocardial infarction or stroke in this 
patient group was not verified in this study. The current 
study is the first to report a link between DM2 and CTCL. 
This link may be related to chronic inflammation, which 
is common in DM2 and MF, the most common form of 
CTCL. Further studies, in larger patient populations, 
are warranted.
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